The subject of this recommendation had $102.0 million in cash and marketable securities as of March 31, 2014. The company will receive two milestone payments of $20 million each this quarter. Moreover, it will most likely get another $150 million or so by next spring, which would lift the cash balance to almost $300 million. That's not all, the development-stage biotechnology concern is in line to receive a royalty stream deriving from a new-drug prospect that by most accounts will be a blockbuster; a recently launched rival product generated an astounding $2.3 billion of sales in its first full quarter on the market. And if that weren't enough, the company has two other collaborations that augur well for the long...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|